Literature DB >> 3068030

Factors affecting metabolic activity of the intestinal microflora.

I R Rowland1.   

Abstract

1. The metabolic activity of the gastrointestinal microflora can be modified by numerous factors derived from the host, the host's environment, and the flora itself. 2. Marked differences exist in microbial composition and metabolism of the gut floras of different species of animal, and in the degree of colonization of the various regions of the gut. 3. The microbial flora changes with age, particularly in early infancy, and developmental changes in in vivo metabolism attributable to the gut flora have been noted for methylmercury. 4. Gastrointestinal disease can have a profound effect on microbial colonization and metabolism in the upper regions of the human gut. In particular, hypochlorhydria can lead to elevation in bacterial numbers, and nitrite and nitrosamine concentrations in gastric juice. 5. Environmental factors such as drugs (particularly antibiotics), diet, and xenobiotics can modify microbial metabolism and toxicity of foreign compounds. In some cases exposure to xenobiotics (e.g., cyclamate, rutin) results in metabolic adaptation and increased biotransformation of the foreign compound. 6. By their fermentation of dietary residues and endogenous carbohydrates, the gut bacteria produce acids which can lower lumenal pH and, in turn, modify bacterial enzyme activities. However, the changes in activity appear to be enzyme specific, some increasing with pH and others being inversely related to pH of incubation.

Entities:  

Mesh:

Year:  1988        PMID: 3068030     DOI: 10.3109/03602538808994135

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  14 in total

1.  Assessment of the human faecal microbiota: I. Measurement and reproducibility of selected enzymatic activities.

Authors:  Roberto Flores; Jianxin Shi; Mitchell H Gail; Jacques Ravel; James J Goedert
Journal:  Eur J Clin Invest       Date:  2012-03-13       Impact factor: 4.686

2.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

3.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 4.  Therapeutic applications of hydrogels in oral drug delivery.

Authors:  Lindsey A Sharpe; Adam M Daily; Sarena D Horava; Nicholas A Peppas
Journal:  Expert Opin Drug Deliv       Date:  2014-06       Impact factor: 6.648

5.  In vitro fermentation of linear and alpha-1,2-branched dextrans by the human fecal microbiota.

Authors:  Shahrul R Sarbini; Sofia Kolida; Thierry Naeye; Alexandra Einerhand; Yoann Brison; Magali Remaud-Simeon; Pierre Monsan; Glenn R Gibson; Robert A Rastall
Journal:  Appl Environ Microbiol       Date:  2011-06-10       Impact factor: 4.792

6.  The metabolism of drugs by the gut flora.

Authors:  M Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

Review 7.  Colon-targeted oral drug delivery systems: design trends and approaches.

Authors:  Seth Amidon; Jack E Brown; Vivek S Dave
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

Review 8.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.

Authors:  Peter Spanogiannopoulos; Elizabeth N Bess; Rachel N Carmody; Peter J Turnbaugh
Journal:  Nat Rev Microbiol       Date:  2016-03-14       Impact factor: 60.633

9.  Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease.

Authors:  O Carrette; C Favier; C Mizon; C Neut; A Cortot; J F Colombel; J Mizon
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

Review 10.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.